Vasculitis & polymyalgia rheumatica
Is there a role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica?
Authors' conclusion
Patients with newly diagnosed GCA or PMR rarely develop PJP.
Study context
- Population
- Incident cases of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in claims data from the TriNetX database
- Participants
- 1,168 vs 15,575
- Comparison
- GCA vs PMR
- GCAn = 1,168
- PMRn = 15,575
- Outcome
- Incidence of PJP
- Follow-up
- First 6 months of therapy
Methodological detailsclaims data (TriNetX database), incident cases
- Claims data (TriNetX database)
- Incident cases
Pooled result
As reported in the abstract
| Group | Value | Follow-up |
|---|---|---|
| GCA | 0 per 1,000 person-years | 547 patient-years |
| PMR | 0.07 cases per 1,000 patient-years | 7,446 patient-years |
Value
GCA0 per 1,000 person-years
PMR0.07 cases per 1,000 patient-years
Follow-up
GCA547 patient-years
PMR7,446 patient-years
Further pooled results
Systematic review: Pneumocystis jiroveci pneumonia (PJP) among patients with GCA or PMR
- Studies identified: case-control studies
- 1
- Studies identified: cohort studies
- 4
- Studies identified: case series / case reports
- 18
- Incident rate of PJP in GCA, one additional study (cases per 1,000 person years)
- 0.08
- Total cases in case series and case reports
- 33
- Total deaths among these cases
- 4
- No additional cohort studies identified for PMR
Original publication
Is there a role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica? Semin Arthritis Rheum. Published 15 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →